^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
HER-2 pulsed DC1
i
Other names: HER-2 pulsed DC1, Human Epidermal Growth Factor Receptor 2 (HER-2) Directed Dendritic Cell (DC1) Vaccine , HER-2 pulsed dendritic cell vaccine, HER-2/neu pulsed dendritic cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
H. Lee Moffitt Cancer Center and Research Institute, ImmunoRestoration, University of Pennsylvania
Drug class:
Immunostimulant, Dendritic cell activator
Related drugs:
3ms
NATASHA: Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab (clinicaltrials.gov)
P2, N=53, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Oct 2025 --> Jan 2025 | Trial primary completion date: Oct 2024 --> Jan 2025
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel • HER-2 pulsed DC1
1year
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab (clinicaltrials.gov)
P2, N=53, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | N=34 --> 53
Enrollment change
|
HER-2 (Human epidermal growth factor receptor 2)
|
Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel • HER-2 pulsed DC1
2years
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab (clinicaltrials.gov)
P2, N=34, Recruiting, H. Lee Moffitt Cancer Center and Research Institute
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel • HER-2 pulsed DC1
Share via
